Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE SODIUM PRESERVATIVE FREE versus OTREXUP PFS.
METHOTREXATE SODIUM PRESERVATIVE FREE vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), preventing the conversion of dihydrofolate to tetrahydrofolate, thereby interfering with DNA synthesis, repair, and cellular replication. It also inhibits thymidylate synthase and purine biosynthesis, and has immunosuppressive and anti-inflammatory effects mediated by adenosine release.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
15-25 mg once weekly orally or intramuscularly for rheumatoid arthritis; 50-75 mg/m2 once weekly intravenously for single-agent acute lymphoblastic leukemia maintenance; 50 mg/m2 intravenously every 2-4 weeks for ectopic pregnancy; 30-40 mg/m2 intravenously once weekly for psoriasis. Dosing varies by indication.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Terminal elimination half-life is 8-15 hours at standard doses; with high-dose therapy (>1 g/m²), half-life extends to 12-24 hours due to saturation of excretion pathways and potential third-space accumulation.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Primarily renal (80-90% excreted unchanged via glomerular filtration and active tubular secretion). Biliary/fecal elimination accounts for <10%.
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite